BACKGROUND: Childhood cancer survivors have a sixfold increased risk of developing subsequent neoplasms when compared to the general population. We sought to describe the occurrence of melanoma as a subsequent neoplasm among adult survivors of childhood cancer. PATIENTS AND METHODS: Among 14,358 5-year survivors of childhood cancer diagnosed between 1970 and 1986, we calculated the cumulative incidence, standardized incidence ratio (SIR), and absolute excess risk (AER) of subsequent melanoma. Potential risk factors were assessed using a cause-specific hazards model. RESULTS: Fifty-seven melanomas (46 invasive, 2 ocular, and 9 in situ) occurred in 51 survivors. The median time to the development of melanoma was 21.0 years (range: 5.6-35.4 years) and the median age at melanoma was 32.3 years (range: 10.9-49.0 years). Initial cancer diagnoses included soft tissue and bone sarcoma (n = 15), leukemia (13), lymphoma (14), central nervous system malignancy (5), Wilms tumor (3), and neuroblastoma (1). The cumulative incidence of first subsequent melanoma at 35 years from initial cancer diagnosis was 0.55% [95% confidence interval (CI): 0.37-0.73]. The SIR of subsequent invasive malignant melanoma of the skin was 2.42 (95% CI: 1.77-3.23), and the AER was 0.10 (95% CI: 0.05-0.15) per 1,000 person-years. No statistically significant associations were found between melanoma risk and family history of cancer, demographic, or treatment-related factors. CONCLUSION: Survivors of childhood cancer have an approximate 2.5-fold increased risk of melanoma. Early screening and prevention strategies are warranted.
BACKGROUND:Childhood cancer survivors have a sixfold increased risk of developing subsequent neoplasms when compared to the general population. We sought to describe the occurrence of melanoma as a subsequent neoplasm among adult survivors of childhood cancer. PATIENTS AND METHODS: Among 14,358 5-year survivors of childhood cancer diagnosed between 1970 and 1986, we calculated the cumulative incidence, standardized incidence ratio (SIR), and absolute excess risk (AER) of subsequent melanoma. Potential risk factors were assessed using a cause-specific hazards model. RESULTS: Fifty-seven melanomas (46 invasive, 2 ocular, and 9 in situ) occurred in 51 survivors. The median time to the development of melanoma was 21.0 years (range: 5.6-35.4 years) and the median age at melanoma was 32.3 years (range: 10.9-49.0 years). Initial cancer diagnoses included soft tissue and bone sarcoma (n = 15), leukemia (13), lymphoma (14), central nervous system malignancy (5), Wilms tumor (3), and neuroblastoma (1). The cumulative incidence of first subsequent melanoma at 35 years from initial cancer diagnosis was 0.55% [95% confidence interval (CI): 0.37-0.73]. The SIR of subsequent invasive malignant melanoma of the skin was 2.42 (95% CI: 1.77-3.23), and the AER was 0.10 (95% CI: 0.05-0.15) per 1,000 person-years. No statistically significant associations were found between melanoma risk and family history of cancer, demographic, or treatment-related factors. CONCLUSION: Survivors of childhood cancer have an approximate 2.5-fold increased risk of melanoma. Early screening and prevention strategies are warranted.
Authors: Katja I Braam; Annelies Overbeek; Gertjan J L Kaspers; Cecile M Ronckers; Annette Y N Schouten-van Meeteren; Eline Van Dulmen-Den Broeder; Margreet A Veening Journal: Pediatr Blood Cancer Date: 2012-01-09 Impact factor: 3.167
Authors: S Guérin; A Dupuy; H Anderson; A Shamsaldin; G Svahn-Tapper; T Moller; E Quiniou; S Garwicz; M Hawkins; M F Avril; O Oberlin; J Chavaudra; F de Vathaire Journal: Eur J Cancer Date: 2003-11 Impact factor: 9.162
Authors: J F McIntyre; B Smith-Sorensen; S H Friend; J Kassell; A L Borresen; Y X Yan; C Russo; J Sato; N Barbier; J Miser Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Ann C Mertens; Pauline A Mitby; Gretchen Radloff; Irene M Jones; John Perentesis; William R Kiffmeyer; Joseph P Neglia; Anna Meadows; John D Potter; Debra Friedman; Yutaka Yasui; Leslie L Robison; Stella M Davies Journal: Cancer Date: 2004-09-15 Impact factor: 6.921
Authors: Yutaka Yasui; Yan Liu; Joseph P Neglia; Debra L Friedman; Smita Bhatia; Anna T Meadows; Lisa R Diller; Ann C Mertens; John Whitton; Leslie L Robison Journal: Am J Epidemiol Date: 2003-12-01 Impact factor: 5.363
Authors: Jop C Teepen; Judith L Kok; Leontien C Kremer; Wim J E Tissing; Marry M van den Heuvel-Eibrink; Jacqueline J Loonen; Dorine Bresters; Helena J van der Pal; Birgitta Versluys; Eline van Dulmen-den Broeder; Tamar Nijsten; Michael Hauptmann; Nynke Hollema; Wil V Dolsma; Flora E van Leeuwen; Cécile M Ronckers Journal: J Natl Cancer Inst Date: 2019-08-01 Impact factor: 13.506
Authors: Stephanie R McKeown; Paul Hatfield; Robin J D Prestwich; Richard E Shaffer; Roger E Taylor Journal: Br J Radiol Date: 2015-10-14 Impact factor: 3.039
Authors: J S Song; W B London; E B Hawryluk; D Guo; M Sridharan; D E Fisher; L E Lehmann; C N Duncan; J T Huang Journal: Bone Marrow Transplant Date: 2017-04-03 Impact factor: 5.483
Authors: Diana R Withrow; Lindsay M Morton; Rochelle E Curtis; Sara J Schonfeld; Amy Berrington de González Journal: Breast Cancer Res Treat Date: 2017-07-25 Impact factor: 4.872
Authors: Lucie M Turcotte; John A Whitton; Debra L Friedman; Sue Hammond; Gregory T Armstrong; Wendy Leisenring; Leslie L Robison; Joseph P Neglia Journal: J Clin Oncol Date: 2015-08-10 Impact factor: 44.544